Tag Archives: BMY stock
Bristol-Myers Squibb (BMY) 24Q3 Update
24Q3 net revenue rose 8.4% to $11.9 billion, with gains in Eliquis, Reblozyl, Breyanzi and Opdivo as well as other medicines from BMY’s growth portfolio more than offsetting an LOE-related decline in Sprycel. Growth portfolio net revenues rose 4% sequentially … Continue reading
Posted in BMY, Health Care
Tagged BMY stock, Bristol-Myers Squibb
Comments Off on Bristol-Myers Squibb (BMY) 24Q3 Update